S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
NASDAQ:MBII

Marrone Bio Innovations - MBII Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$0.80
$0.80
50-Day Range
$0.80
$0.80
52-Week Range
$0.55
$1.55
Volume
38 shs
Average Volume
919,497 shs
Market Capitalization
$145.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.30

Marrone Bio Innovations MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
62.9% Upside
$1.30 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-11.74
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.06) to ($0.02) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.44 out of 5 stars

Basic Materials Sector

154th out of 164 stocks

Agricultural Chemicals Industry

9th out of 9 stocks

MBII stock logo

About Marrone Bio Innovations (NASDAQ:MBII) Stock

Marrone Bio Innovations, Inc. discovers, develops, and sells biological products for crop protection, crop health, and crop nutrition. Its products include Emergen, Foramin, Foramin ST, Optima, Takla, Pacesetter, Ympact, UBP, and UBP ST for increasing crop health, yield, and quality; Grandevo, a bioinsecticide that controls sucking and chewing insects through feeding; Haven, a plant health product to reduce sun stress and dehydration; Jet-Ag and Jet-Oxide peroxyacetic acid sanitizers that prevent, suppress, eliminate, and control algae, fungi, and bacterial diseases in agriculture and horticultural industries; and Majestene, a bionematicide to control soil-dwelling nematodes and certain soil borne insects. The company also offers Regalia and Stargus, which protects against fungal and bacterial diseases and enhances yields/quality; Venerate, a bioinsecticide that controls chewing and sucking insects and mites; and Zelto, a bionematicide that protects turf, including golf course fairways and greens, and promotes turf health by enhancing plant and root health. It provides its products directly through sales force, as well as through distributors and other commercial partners. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was incorporated in 2006 and is headquartered in Raleigh, North Carolina.

Receive MBII Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marrone Bio Innovations and its competitors with MarketBeat's FREE daily newsletter.

MBII Stock News Headlines

MBI: Body found in Forrest Co. identified
Marrone name goes away in sale to Bioceres
Mid-Afternoon Market Update: Nasdaq Down 3%; Accolade Shares Slide
Preview: Marrone Bio Innovations's Earnings
See More Headlines

Receive MBII Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marrone Bio Innovations and its competitors with MarketBeat's FREE daily newsletter.

MBII Company Calendar

Last Earnings
11/10/2021
Today
12/07/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Agricultural Chemicals
Sub-Industry
N/A
Current Symbol
NASDAQ:MBII
Fax
N/A
Employees
153
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$1.30
High Stock Price Forecast
$1.30
Low Stock Price Forecast
$1.30
Forecasted Upside/Downside
+62.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-16,550,000.00
Pretax Margin
-47.12%

Debt

Sales & Book Value

Annual Sales
$44.31 million
Book Value
$0.17 per share

Miscellaneous

Free Float
173,259,000
Market Cap
$145.56 million
Optionable
Not Optionable
Beta
0.36

Key Executives

  • Mr. Kevin R. Helash (Age 57)
    CEO & Director
    Comp: $416.64k
  • Dr. Pamela G. Marrone Ph.D. (Age 65)
    Founder, Advisor & Non-Employee Director
    Comp: $254.58k
  • Ms. Linda V. Moore (Age 75)
    Chief Compliance Officer, Chief Legal Officer & Sec.
    Comp: $316.74k
  • Mr. LaDon Johnson CPA
    CPA, Interim Chief Financial Officer
  • Dr. Amit Vasavada Ph.D. (Age 67)
    Sr. VP of Research Devel. & Chief Technical Officer
  • Andre Trepanier
    Director of Marketing
  • Mr. Barner Jones
    Director of National Sales & Account Management
  • Mr. Matti Tiainen (Age 33)
    Sr. VP of International Sales
  • Mr. Keith J. Pitts (Age 58)
    Sr. VP of Regulatory & Gov. Affairs and Chief Sustainability Officer













MBII Stock - Frequently Asked Questions

Should I buy or sell Marrone Bio Innovations stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Marrone Bio Innovations in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MBII shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MBII, but not buy additional shares or sell existing shares.
View MBII analyst ratings
or view top-rated stocks.

What is Marrone Bio Innovations' stock price forecast for 2023?

1 equities research analysts have issued 1-year price targets for Marrone Bio Innovations' shares. Their MBII share price forecasts range from $1.30 to $1.30. On average, they predict the company's share price to reach $1.30 in the next year. This suggests a possible upside of 62.9% from the stock's current price.
View analysts price targets for MBII
or view top-rated stocks among Wall Street analysts.

How were Marrone Bio Innovations' earnings last quarter?

Marrone Bio Innovations, Inc. (NASDAQ:MBII) issued its quarterly earnings data on Wednesday, November, 10th. The basic materials company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.03). The basic materials company earned $9.86 million during the quarter, compared to analysts' expectations of $10.79 million. Marrone Bio Innovations had a negative trailing twelve-month return on equity of 70.87% and a negative net margin of 47.07%. During the same period in the previous year, the firm posted ($0.04) earnings per share.

What other stocks do shareholders of Marrone Bio Innovations own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marrone Bio Innovations investors own include Ekso Bionics (EKSO), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), KushCo (KSHB), Enerplus (ERF), ADMA Biologics (ADMA), Great Panther Mining (GPL), OrganiGram (OGI), Aeterna Zentaris (AEZS).

What is Marrone Bio Innovations' stock symbol?

Marrone Bio Innovations trades on the NASDAQ under the ticker symbol "MBII."

What is Marrone Bio Innovations' stock price today?

One share of MBII stock can currently be purchased for approximately $0.80.

How much money does Marrone Bio Innovations make?

Marrone Bio Innovations (NASDAQ:MBII) has a market capitalization of $145.56 million and generates $44.31 million in revenue each year. The basic materials company earns $-16,550,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis.

How many employees does Marrone Bio Innovations have?

The company employs 153 workers across the globe.

How can I contact Marrone Bio Innovations?

Marrone Bio Innovations' mailing address is 1540 Drew Avenue, Davis CA, 95618. The official website for the company is www.marronebioinnovations.com. The basic materials company can be reached via phone at (530) 750-2800 or via email at ir@marronebio.com.

This page (NASDAQ:MBII) was last updated on 12/8/2022 by MarketBeat.com Staff